PMID- 35163615
OWN - NLM
STAT- MEDLINE
DCOM- 20220330
LR  - 20220330
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 23
IP  - 3
DP  - 2022 Feb 1
TI  - Predominant Role of mTOR Signaling in Skin Diseases with Therapeutic Potential.
LID - 10.3390/ijms23031693 [doi]
LID - 1693
AB  - The serine/threonine kinase mechanistic target of rapamycin (mTOR) plays a 
      pivotal role in the regulation of cell proliferation, survival, and motility in 
      response to availability of energy and nutrients as well as mitogens. The mTOR 
      signaling axis regulates important biological processes, including cellular 
      growth, metabolism, and survival in many tissues. In the skin, dysregulation of 
      PI3K/AKT/mTOR pathway may lead to severe pathological conditions characterized by 
      uncontrolled proliferation and inflammation, including skin hyperproliferative as 
      well as malignant diseases. Herein, we provide an update on the current knowledge 
      regarding the pathogenic implication of the mTOR pathway in skin diseases with 
      inflammatory features (such as psoriasis, atopic dermatitis, pemphigus, and acne) 
      and malignant characteristics (such as cutaneous T cell lymphoma and melanoma) 
      while we critically discuss current and future perspectives for therapeutic 
      targeting of mTOR axis in clinical practice.
FAU - Karagianni, Fani
AU  - Karagianni F
AUID- ORCID: 0000-0001-9514-2199
AD  - National Center of Rare Diseases-Cutaneous Lymphoma, Second Department of 
      Dermatology and Venereal Diseases, Attikon University General Hospital, National 
      and Kapodistrian University of Athens, 12462 Athens, Greece.
FAU - Pavlidis, Antreas
AU  - Pavlidis A
AUID- ORCID: 0000-0001-5689-1795
AD  - National Center of Rare Diseases-Cutaneous Lymphoma, Second Department of 
      Dermatology and Venereal Diseases, Attikon University General Hospital, National 
      and Kapodistrian University of Athens, 12462 Athens, Greece.
FAU - Malakou, Lina S
AU  - Malakou LS
AD  - Department of Biological Chemistry, Medical School, National and Kapodistrian 
      University of Athens, 11527 Athens, Greece.
FAU - Piperi, Christina
AU  - Piperi C
AUID- ORCID: 0000-0002-2701-0618
AD  - Department of Biological Chemistry, Medical School, National and Kapodistrian 
      University of Athens, 11527 Athens, Greece.
FAU - Papadavid, Evangelia
AU  - Papadavid E
AD  - National Center of Rare Diseases-Cutaneous Lymphoma, Second Department of 
      Dermatology and Venereal Diseases, Attikon University General Hospital, National 
      and Kapodistrian University of Athens, 12462 Athens, Greece.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220201
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Animals
MH  - Humans
MH  - Inflammation
MH  - Molecular Targeted Therapy
MH  - *Signal Transduction
MH  - Skin Diseases/drug therapy/*metabolism
MH  - TOR Serine-Threonine Kinases/*metabolism
PMC - PMC8835793
OTO - NOTNLM
OT  - acne
OT  - atopic dermatitis
OT  - cutaneous T cell lymphoma
OT  - inhibitors
OT  - mTOR signaling pathway
OT  - melanoma
OT  - pemphigus
OT  - psoriasis
OT  - therapy
COIS- The authors declare no conflict of interest.
EDAT- 2022/02/16 06:00
MHDA- 2022/03/31 06:00
PMCR- 2022/02/01
CRDT- 2022/02/15 01:18
PHST- 2021/12/28 00:00 [received]
PHST- 2022/01/30 00:00 [revised]
PHST- 2022/01/31 00:00 [accepted]
PHST- 2022/02/15 01:18 [entrez]
PHST- 2022/02/16 06:00 [pubmed]
PHST- 2022/03/31 06:00 [medline]
PHST- 2022/02/01 00:00 [pmc-release]
AID - ijms23031693 [pii]
AID - ijms-23-01693 [pii]
AID - 10.3390/ijms23031693 [doi]
PST - epublish
SO  - Int J Mol Sci. 2022 Feb 1;23(3):1693. doi: 10.3390/ijms23031693.